Dariohealth Corp - DRIO STOCK NEWS

DarioHealth Corp. (Nasdaq: DRIO) has announced a partnership with Dexcom (Nasdaq: DXCM) to integrate continuous glucose monitoring (CGM) data into its digital therapeutics platform. This integration aims to enhance access to Dario's multi-chronic condition management solutions for diabetes patients. With nearly two million users of CGMs, the collaboration is expected to provide personalized support through real-time glucose data. This follows Dario's strategic agreement with Sanofi US, further expanding its digital health ecosystem. The initiative highlights Dario's commitment to enhancing the user experience and meeting market demand for integrated health solutions.

DarioHealth Corp. (NASDAQ: DRIO) announced preliminary unaudited revenue results for 2022, projecting total revenue of $27.5 million, up from $20.5 million in 2021. The shift from Business-to-Consumer (B2C) to Business-to-Business (B2B) is highlighted, with B2B expected to account for 60% of revenue in 2022, a significant increase from 4% in 2021. Operating loss was reduced by over 50% compared to Q4 2021. The company finished 2022 with $49.3 million in cash and begins quarterly payments of $1.5 million on its credit facility with Orbimed in January 2023. Final audited results may differ from preliminary estimates.

DarioHealth Corp. (NASDAQ: DRIO) announced the hiring of Matt Alberico as Senior Vice President of Growth to accelerate growth opportunities in the digital therapeutics market. Alberico previously drove customer growth at Amazon Care, Cigna, and Aetna. His extensive sales strategy experience is expected to help Dario capitalize on increasing market demand for integrated health solutions, following the signing of their 100^th contract. Additionally, Alberico received stock options totaling 100,000 shares at an exercise price of $5.97, vesting over a three-year period.

DarioHealth Corp. (Nasdaq: DRIO) announced new research published in Applied Sciences demonstrating improved diabetes outcomes across racial and ethnic groups. The study analyzed data from 1,000 Type 2 diabetes users over 12 months, showing a 14% reduction in average blood glucose for White users and a 15% reduction for Black, Latino, and Asian users. The findings indicate that Dario's digital therapeutics platform effectively engages users without racial disparities in outcomes and emphasizes the company's commitment to addressing health inequities through digital health solutions.

DarioHealth Corp. (NASDAQ: DRIO) announced a partnership with a major Northeast supermarket chain to enhance employees' cardiometabolic health starting in Q1 2023. This contract marks Dario's achievement of 100 enterprise contracts, validating its strategic position in the digital therapeutics market. The suite focuses on managing diabetes, hypertension, and weight management via integrated solutions. The Company anticipates growth due to increasing demand for multi-condition solutions from enterprise customers.

DarioHealth Corp. (NASDAQ: DRIO) announced a study published in Frontiers in Physiology on Dec. 19, 2022, showcasing its musculoskeletal solution's effectiveness in alleviating back pain. The research analyzed data from 981 users over eight weeks, revealing a 50% average reduction in pain, with 60% of users reporting significant relief after four weeks. The device offers real-time biofeedback to improve posture, resulting in better pain management. Dario's commitment to changing health management behaviors through innovative technology is emphasized, showing potential for chronic pain treatment.

DarioHealth Corp. (Nasdaq: DRIO) announced participation in two upcoming investor conferences. The 13th Annual Craig-Hallum Alpha Select Conference will take place on November 17, 2022, in New York City, featuring investor one-on-one meetings. Additionally, the BTIG Digital Health Forum is scheduled for November 21, 2022, as a virtual event, where President Rick Anderson will discuss digital therapeutics at 11:55 a.m. EST. DarioHealth focuses on digital solutions for chronic condition management, delivering personalized care through analytics and coaching.

DarioHealth Corp. (Nasdaq: DRIO) reported third quarter 2022 revenues of $6.6 million, a 17.3% increase from the previous year, driven by strong B2B growth, which now constitutes 63.5% of total revenue. The net loss decreased by 30.3% to $15.6 million. Notably, the company signed 85 B2B contracts valued at over $61 million, with a goal of reaching 100 by year-end. Operating expenses fell by 29.8%, contributing to improved financial health and gross margins of approximately 70% in the B2B segment. A conference call will be held on November 15, 2022.